97 related articles for article (PubMed ID: 29181416)
1. CD80 Expressed by CD8
Rollins MR; Gibbons Johnson RM
J Immunol Res; 2017; 2017():7659462. PubMed ID: 29181416
[TBL] [Abstract][Full Text] [Related]
2. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
3. Programmed death receptor 1 (PD-1) ligand Fc fusion proteins reduce T-cell proliferation in vitro independently of PD-1.
Biemond M; Vremec D; Gray DH; Hodgkin PD; Heinzel S
Immunol Cell Biol; 2024 Feb; 102(2):117-130. PubMed ID: 38069638
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.
Piao W; Li L; Saxena V; Iyyathurai J; Lakhan R; Zhang Y; Lape IT; Paluskievicz C; Hippen KL; Lee Y; Silverman E; Shirkey MW; Riella LV; Blazar BR; Bromberg JS
Nat Commun; 2022 Apr; 13(1):2176. PubMed ID: 35449134
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic Evaluation of CD80, CD86, and PD-L1 Expressions with Immunohistochemical Methods in Malignant Melanoma Patients.
Cobankent Aytekin E; Unal B; Bassorgun CI; Ozkan O
Turk Patoloji Derg; 2024; 40(1):16-26. PubMed ID: 37614091
[TBL] [Abstract][Full Text] [Related]
6. Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes.
Becker MW; Peters LD; Myint T; Smurlick D; Powell A; Brusko TM; Phelps EA
Sci Adv; 2023 Jun; 9(22):eadg1082. PubMed ID: 37267353
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80.
Shahbandi A; Chiu FY; Ungerleider NA; Kvadas R; Mheidly Z; Sun MJS; Tian D; Waizman DA; Anderson AY; Machado HL; Pursell ZF; Rao SG; Jackson JG
Nat Cancer; 2022 Dec; 3(12):1513-1533. PubMed ID: 36482233
[TBL] [Abstract][Full Text] [Related]
8. CD80-Fc fusion protein as a potential cancer immunotherapy strategy.
Wang S; Hu P; Fan J; Zou J; Hong W; Huang X; Pan D; Chen H; Zhu YZ; Ye L
Antib Ther; 2024 Jan; 7(1):28-36. PubMed ID: 38235375
[TBL] [Abstract][Full Text] [Related]
9. The complex role of PD-L1 in antitumor immunity: a recent update.
Zhang X; Huang Y; Yang X
Cell Mol Immunol; 2021 Aug; 18(8):2067-2068. PubMed ID: 34059793
[No Abstract] [Full Text] [Related]
10. Transcription Factor IRF4 Promotes CD8
Man K; Gabriel SS; Liao Y; Gloury R; Preston S; Henstridge DC; Pellegrini M; Zehn D; Berberich-Siebelt F; Febbraio MA; Shi W; Kallies A
Immunity; 2017 Dec; 47(6):1129-1141.e5. PubMed ID: 29246443
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer.
Cui S; Su X; Dong L; Qian J; Ye L; Zhang T; Fu H; Han H; Huang J; Yao Y; Gu Y; Jiang L
J Cancer; 2017; 8(19):4075-4082. PubMed ID: 29187883
[No Abstract] [Full Text] [Related]
12. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
13. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
14. Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity.
Abdul Karim L; Kallakury BVS; Chahine JJ; Sheehan CE; Ross JS
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e22. PubMed ID: 29189261
[No Abstract] [Full Text] [Related]
15. Restriction of PD-1 function by
Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model.
Miura Y; Isogai S; Maeda S; Kanazawa S
Sci Rep; 2022 Sep; 12(1):16363. PubMed ID: 36180526
[TBL] [Abstract][Full Text] [Related]
17. B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5-β-catenin pathway.
Li J; Niu J; Min W; Ai J; Lin X; Miao J; Zhou S; Liang Y; Chen S; Ren Q; Shen K; Wu Q; Li X; Shen W; Hou FF; Liu Y; Yang P; Zhou L
Cell Death Differ; 2022 Dec; 29(12):2399-2416. PubMed ID: 35710882
[TBL] [Abstract][Full Text] [Related]
18. Expression of Murine CD80 by Herpes Simplex Virus 1 in Place of Latency-Associated Transcript (LAT) Can Compensate for Latency Reactivation and Anti-apoptotic Functions of LAT.
Jaggi U; Matundan HH; Tormanen K; Wang S; Yu J; Mott KR; Ghiasi H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852788
[TBL] [Abstract][Full Text] [Related]
19. CD80 Plays a Critical Role in Increased Inflammatory Responses in Herpes Simplex Virus 1-Infected Mouse Corneas.
Tormanen K; Wang S; Ghiasi H
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619558
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of the expressed cluster differentiation markers proteins type 20 and 56 in breast tissues from a group of Iraqi patients with breast cancers.
Zeiny SMH; Mohammed Ali SH
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3621-3628. PubMed ID: 37898871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
